Krystal Biotech's B-VEC for Dystrophic Epidermolysis Bullosa Gets Expanded FDA Label

FDA expands B-VEC label to include patients from birth with dystrophic epidermolysis bullosa

The updated label is based on real-world data collected since B-VEC was launched in the United States, following its approval in May of 2023.

Krystal Biotech's B-VEC for Dystrophic Epidermolysis Bullosa Gets Expanded FDA Label

Krystal Biotech enhances B-VEC's label, empowering DEB patients with at-home treatment options and improving quality of life through innovative gene therapy.

FDA expands label for Krystal’s gene therapy; The latest on Novo Nordisk’s Wegovy

Plus, news about Revvity, Ocugen and Kwangdong: 🏛️ FDA expands label for Krystal Biotech’s gene therapy: Vyjuvek, which is used to treat a skin condition called dystrophic epidermolysis bullosa, is now